Status:
COMPLETED
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
Eligibility Criteria
Inclusion
- relapsed or refractory Hodgkin Lymphoma
- age 18-60
- histology confirmed relapse
Exclusion
- previous therapy with mTOR inhibitor
- current CNS involvement
- other primary malignant disease within the last 3 years
Key Trial Info
Start Date :
August 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2019
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT01453504
Start Date
August 1 2012
End Date
March 1 2019
Last Update
November 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany